Epivir-HBV

See also: Generic Epivir

Epivir-HBV is a brand name of lamivudine, approved by the FDA in the following formulation(s):

EPIVIR-HBV (lamivudine - solution; oral)

• 
  Manufacturer: GLAXOSMITHKLINE
  
  Approval date: December 8, 1998
  
  Strength(s): 5MG/ML ^[RLD]

EPIVIR-HBV (lamivudine - tablet; oral)

• 
  Manufacturer: GLAXOSMITHKLINE
  
  Approval date: December 8, 1998
  
  Strength(s): 100MG ^[RLD]

Has a generic version of Epivir-HBV been approved?

No. There is currently no therapeutically equivalent version of Epivir-HBV available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Epivir-HBV. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Crystalline oxathiolane derivatives
  Patent 5,905,082
  Issued: May 18, 1999
  Inventor(s): Roberts; Tony Gordon & Evans; Paul
  Assignee(s): Glaxo Group Limited
  (-)cis-4-Amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(IH)-pyrimidine-2-on e in crystalline form, in particular as needle-shaped or bypyramidyl crystals, pharmaceutical formulations thereof, methods for their preparation and their use in medicine.
  
  Patent expiration dates:
  
  
  • May 18, 2016
    
  
  
  
  • November 18, 2016
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Pharmaceutical compositions containing lamivudine
  Patent 6,004,968
  Issued: December 21, 1999
  Inventor(s): Casey; Warren Michael & Nguyen; Ngoc-Anh Thi
  Assignee(s): Glaxo Wellcome Inc.
  The present invention relates to pharmaceutical formulations containing (2R, cis)-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2 -one (-)-2',3'-dideoxy,3'-thiacytidine, lamivudine, that are substantially free of ethanol and ethylenediamine-tetraacitic acid, and their use in medical therapy.
  
  Patent expiration dates:
  
  
  • March 20, 2018
    
  
  
  
  • September 20, 2018
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Use of 1,3-oxathiolane nucleoside analogues in the treatment of hepatitis B
  Patent RE39155
  Issued: July 4, 2006
  Inventor(s): Nguyen-Ba; Nghe
  Assignee(s): Shire BioChem Inc.
  Use of a compound of formula (I) or a pharmaceutically acceptable derivative thereof in the manufacture of a medicament for the treatment of hepatitis B is disclosed.
  
  Patent expiration dates:
  
  
  • July 2, 2013
    
    ✓ 
    Patent use: TREATMENT OF HEPATITIS B INFECTION
  
  
  
  • January 2, 2014
    
    ✓ 
    Pediatric exclusivity
  
  

See also...

• Epivir-HBV Consumer Information (Wolters Kluwer)
• Epivir-HBV Solution Consumer Information (Wolters Kluwer)
• Epivir HBV Consumer Information (Cerner Multum)
• Epivir HBV Advanced Consumer Information (Micromedex)
• Lamivudine Consumer Information (Wolters Kluwer)
• Lamivudine Solution Consumer Information (Wolters Kluwer)
• Lamivudine Consumer Information (Cerner Multum)
• 3tc Advanced Consumer Information (Micromedex)
• Epivir A/F Advanced Consumer Information (Micromedex)
• Heptovir Advanced Consumer Information (Micromedex)
• Lamivudine Advanced Consumer Information (Micromedex)
• Lamivudine AHFS DI Monographs (ASHP)